Weight Loss in Cancer and the 2017 Common Terminology Criteria for Adverse Events—Dangerous and Misleading
ABSTRACT Accurate toxicity reporting in cancer clinical trials is necessary to promote regulatory decision making. Up to 85% of those with some cancers (e.g., oesophagus, head and neck, and pancreas) experience significant progressive weight loss (WL) throughout treatment. Therefore, it is necessary...
Saved in:
| Main Authors: | Aynur Aktas, Kunal C. Kadakia, Jake Waldman, Declan Walsh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Journal of Cachexia, Sarcopenia and Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jcsm.13754 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characterization of adverse reactions to four common targeted drugs for hepatocellular carcinoma in WHO-VigiAccess
by: Zeyu Wang, et al.
Published: (2025-05-01) -
The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01) -
Large‐scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in Arabidopsis
by: Naoyuki Sugiyama, et al.
Published: (2008-05-01) -
Incidence and prevalence of organ toxicities in patients suffering from clear cell renal carcinoma treated with sunitinib and its impact on survival: a reference cancer center experience
by: Agata Sałek-Zań, et al.
Published: (2025-08-01) -
Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
by: I. S. Romanov, et al.
Published: (2020-07-01)